ClearPoint Neuro, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2025 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	(b) During our last fiscal quarter, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any Rule 10b5-1 trading arrangement (as defined in Item 408(a)(1)(i) of Regulation S-K) or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K), except as described below. On November 26, 2025, Danilo D'Alessandro, our Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement intended to satisfy the Rule 10b5-1 affirmative defense. The trading arrangement expires November 30, 2026, subject to earlier expiration if all transactions thereunder are completed before the scheduled expiration date. A total of 64,278 shares are subject to the plan.
Other Directors or Officers
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Danilo D'Alessandro
Trading Arrangements, by Individual
Name	Danilo D'Alessandro
Title	Chief Financial Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	November 26, 2025
Expiration Date	November 30, 2026
Aggregate Available	64,278